Cassandra Hubbart, DailyFinance If you think your credit score doesn't matter too much to you because you're not planning on getting a mortgage or applying for a credit card anytime soon, think again. Credit scores affect more aspects of our lives than you may realize (just ask these singles). That's why it's important to keep your score as high as possible. Paying your bills on time and staying well below your credit limits are the best ways to build and maintain good credit. Together they account for more than half of your overall credit score. A healthy payment history is the biggest contributor to your credit score, accounting for 35 percent of the total. Miss even a single deadline, and you could see your credit score drop as much as 100 points or more. To avoid those dreaded "overdue" notices and the credit blemishes they bring, set up automatic payments for any regular bills so that your lenders get the check on time, every single time. Another 30 percent of your credit score is based on the amount of debt you carry, as measured against the amount of available credit you have -- otherwise known as your credit utilization ratio. It's a good idea to keep your outstanding balances to less than 25 percent of the money available to you to spend. If you are not able to pay down your balances ASAP, you can go at the problem from a different angle by calling your lenders and asking them to raise your credit limit. But beyond these basic rules of smart credit management, there are some lesser-known strategies that can help you boost your score. Check your credit reports and correct errors. Of course, you want to make sure that everything is being accurately reported, from your current address to your closed accounts. (For more guidance on how to dispute an error on your credit report, look to this guide from the Federal Trade Commission.)
Top 5 Supermarket Companies To Watch In Right Now: Grupo Financiero Galicia S.A. (GGAL)
Grupo Financiero Galicia S.A. operates as a financial services holding company in Argentina. The company offers financial products and services, including collection and payment services, commercial credit cards, direct payroll deposits, capital market alternatives, foreign trade solutions, and corporate e-banking solutions; corporate debt transactions and securitization transactions; and e-collection and payment solutions to various agencies, municipalities, and universities. It also provides a range of financial products and services, such as transactions, loans, and investments; and checking and savings accounts, credit and debit cards, payroll direct deposits, insurance, and retirement and pension payments. In addition, the company offers mutual funds and in brokerage services; manages positions in foreign currency and government securities; acts as an intermediary and distributes financial instruments for institutional investors, corporate customers, and individuals; and enables customers to buy and sell securities on the Buenos Aires Stock Exchange. Further, it provides life insurance products, including employee benefit plans and credit related insurance; and property and casualty insurance products, such as home and ATM theft insurance. As of December 31, 2012, the company operated 257 full service banking branches and 1,676 ATMs and self-service terminals. Grupo Financiero Galicia S.A. was founded in 1905 and is based in Buenos Aires, Argentina.
Advisors' Opinion:- [By Federico Zaldua]
Grupo Financiero Galicia (GGAL), which was once owned by Rob Citrone's hedge fund Discovery Capital Management, owns one of Argentina's biggest private banks by deposits and the fastest growing within the banks that count with national presence. As a matter of fact, according to management, "the bank's estimated market share of loans to private sector was 9.10% growing 56 basis points from a year before and the market share of deposits from the private sector was 8.98% growing 28 basis points in the year."
Best Net Payout Yield Companies To Buy Right Now: Vanguard Reit Etf (VNQ)
Vanguard REIT ETF (the Fund), formerly known as Vanguard REIT VIPERs, is an exchange-traded share class of Vanguard REIT Index Fund. The Fund seeks to provide a high level of income and moderate long-term capital appreciation by tracking the performance of an index that measures the performance of publicly traded equity real estate investment trusts (REITs). Vanguard REIT ETF employs a passive management or indexing investment approach designed to track the performance of the MSCI US REIT Index (the Index), an index of United States property trusts that covers about two-thirds of the value of the entire United States REIT market.
Vanguard REIT ETF normally invests approximately 98% of assets in stocks issued by equity REITs. The Fund invests in the stocks that make up the Index, and the remaining assets are allocated to cash investments.
Advisors' Opinion:- [By Dan Caplinger]
Keeping it simple
Some advisors will suggest that you're giving up big potential returns if you don't pick individual stocks. But a portfolio that relies on the broad-based ETFs Vanguard Total Stock Market (NYSEMKT: VTI ) , iShares Core Bond Market (NYSEMKT: AGG ) , Vanguard REIT (NYSEMKT: VNQ ) , or other similar ETFs from other fund companies will get you most of the way to the returns that you need in order to retire comfortably. These three ETFs are particularly useful because they come with low fees, but as long as the ETF you choose doesn't charge too much, there are plenty of strong options to pick from. Insurance coverage can be extremely difficult to understand, and the costs involved can be high. Sticking with basic insurance early on and later adding features as you become more familiar with the risks involved might not always be the least expensive solution to your insurance needs, as in some cases, the earlier you get coverage, the less it costs. Moreover, you won't always qualify to get insurance if some event occurs later in life that boosts your risk to the point at which insurance companies won't offer you coverage at all. But the wait-and-see strategy does have the benefit of preventing you from getting coverage that might well be obsolete or unnecessary by the time you seek to use it.
Even though retirement planning can get complicated in a hurry, the key to remember throughout much of your career is that it's impossible to plan for every contingency you'll face. As a result, the simpler way to handle planning for retirement is to address the threats that you can control while maintaining as much flexibility as possible to handle the threats you can't control -- or might not even be aware of. A few examples include:Admittedly, these simple solutions won't always take care of every contingency, and they can leave you vulnerable to certain risks that require advanced planning techniques. But
- [By Dan Caplinger]
3. Real-estate investment trusts
Rate-sensitive REITs took another big hit over the week, with the Vanguard REIT ETF (NYSEMKT: VNQ ) dropping more than 5%. Leveraged mortgage REITs saw even worse losses, with Annaly Capital (NYSE: NLY ) falling more than 7% and American Capital Agency (NASDAQ: AGNC ) seeing 8% declines.
Best Net Payout Yield Companies To Buy Right Now: Cooper Companies Inc (COO)
The Cooper Companies, Inc., incorporated on March 4, 1980, is a global medical device company. The Company operates through two business units, CooperVision, Inc. and CooperSurgical, Inc. CooperVision is a global manufacturer providing products for contact lens wearers. CooperSurgical focuses on supplying women's health clinicians with products and treatment options to improve the delivery of healthcare to women.
CooperVision develops, manufactures and markets a range of monthly, two-week and single-use contact lenses, featuring advanced materials and optics. CooperVision's products are designed to solve vision challenges such as astigmatism, presbyopia and ocular dryness with a collection of spherical, toric and multifocal contact lenses. CooperVision's products are primarily manufactured at its facilities located in Hampshire, United Kingdom, Juana Diaz, Puerto Rico, and Scottsville, New York. CooperVision distributes products from West Henrietta, New York, Fareham, United Kingdom, Liege, Belgium, and various smaller international distribution facilities. Under the Biofinity brand, CooperVision has launched monthly silicone hydrogel spherical, toric and multifocal lens products. CooperVision has also launched two-week silicone hydrogel spherical and toric lens products under its Avaira brand. During the fiscal year ended October 31, 2013 (fiscal 2013), the Company launched MyDay, its single-use spherical silicone hydrogel lens, in Europe. CooperVision's Proclear line of spherical, toric and multifocal lenses are manufactured with omafilcon, a material that incorporates Phosphorylcholine (PC) Technology that helps enhance tissue-device compatibility.
CooperSurgical offers an array of products used in the care and treatment of women's health. The Company participates in the women's healthcare market through offering quality products, technologies and service to clinicians worldwide. CooperSurgical collaborates with clinicians to identify products and new technologies from dis! posable products to instruments and equipment. The result is a portfolio of products that aid in the delivery of improved clinical outcomes that healthcare professionals use routinely in the diagnosis and treatment of a wide spectrum of women's health issues.
The Company competes with Johnson & Johnson Vision Care, Inc., CIBA Vision, Bausch & Lomb Incorporated, Boston Scientific, Johnson & Johnson's Ethicon Endo-Surgery and Ethicon Women's Health and Urology companies, Gyrus ACMI and Covidien.
Advisors' Opinion:- [By Chuck Carnevale]
The following example looking at Cooper Cos. Inc. (COO), and reveals a very cyclical company that provides insight into the PE equals 15 hypotheses that this series of articles has presented. Clearly, price follows earnings even when earnings are dropping, and interestingly, the market tends to apply our standard PE equals 15 even when this happens.
- [By Johanna Bennett]
Copper Cos (COO) shrank 6.5% to $125 after fiscal fourth-quarter earnings and the company�� full-year 2014 financial forecasts fell below expectations. For the period ended Oct. 31, Cooper earned $57.4 million, or $1.15 a share, down from $71.9 million, or $1.46 a share, in the prior-year period. Excluding impacts from a divestiture, adjusted earnings were $1.48, up from $1.47. Revenue gained 3.9% to $411.9 million. Excluding currency impacts, the growth was 7%. �For the new fiscal year, Cooper said it expects per-share earnings of $6.70 to $7 and revenue of $1.675 billion to $1.735 billion Analysts polled by Thomson Reuters were expecting $7 a share in profit and $1.71 billion in revenue.
Best Net Payout Yield Companies To Buy Right Now: Glu Mobile Inc.(GLUU)
Glu Mobile Inc. designs, markets, and sells mobile games worldwide. It develops original games based on its intellectual property comprising Big Time Gangsta?, Blood & Glory, Bug Village, Contract Killer, Contract Killer: Zombies, Eternity Warriors, Frontline Commando, Gun Bros, Men vs. Machines, Stardom: The A-List, Super K.O. Boxing and Toyshop Adventures. The company also develops games based on licensed intellectual property consisting of Build-a-lot, Call of Duty, Deer Hunter, DJ Hero, Guitar Hero, Family Feud, Family Guy, Lord of the Rings, Paperboy, The Price Is Right, Transformers, Who Wants to Be a Millionaire?, and World Series of Poker. It offers a portfolio of action/adventure and casual games to smartphones and tablet devices users through direct-to-consumer digital storefronts, as well as to feature phone users served by wireless carriers and other distributors. The company was formerly known as Sorrent, Inc. and changed its name to Glu Mobile Inc. in May 20 05. Glu Mobile Inc. was incorporated in 2001 and is headquartered in San Francisco, California.
Advisors' Opinion:- [By kcpl]
Glu Mobile (GLUU) is off to a solid start in 2014 with impressive results, driven by strong execution and the popularity of its games such as Deer Hunter and Eternity Warriors.
- [By Jayson Derrick]
Analysts at Benchmark downgraded Glu Mobile (NASDAQ: GLUU) to Hold from Buy. Shares lost 18.70 percent, closing at $5.61.
Recommended: 5 Cool Items To Buy From The Amazon 3D Printing Store
- [By Iampat]
Glu Mobile (GLUU) is currently procuring the accomplishment of the moves that it made in its past item cycle to adapt its games in a finer and more proficient way. Its procedure of concentrating on leveraging stage quality and making long haul gaming establishments has demonstrated profitable. The launch of new games, for example, Robocop, Defenders & Dragons and Motocross Meltdown have been key impetuses for Glu Mobile. Likewise, the launch of Deer Hunter on Facebook (FB) is additionally driving reception over a higher number of clients.
Best Net Payout Yield Companies To Buy Right Now: Inovio Pharmaceuticals Inc (INO)
Inovio Pharmaceuticals, Inc., incorporated on June 29, 1983, is engaged in the development of a new generation of vaccines, called synthetic vaccines, focused on cancers and infectious diseases. The Company's SynCon technology enables the design of universal vaccines capable of providing cross-protection against existing or changing strains of pathogens, such as influenza and human immunodeficiency virus (HIV). The Company's electroporation delivery technology uses brief, controlled electrical pulses to increase cellular uptake of the vaccine. Its clinical programs include cervical dysplasia (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus (HCV) and HIV vaccines. It is advancing preclinical research and clinical development for a universal seasonal/pandemic influenza vaccine, as well as preclinical work for other products, including malaria and prostate cancer vaccines. Its partners and collaborators include University of Pennsylvania, Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, Program for Appropriate Technology in Health/Malaria Vaccine Initiative (PATH/MVI), National Institute of Allergy and Infectious Diseases (NIAID), Merck, ChronTech, University of Southampton, United States Military HIV Research Program (USMHRP), the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and HIV Vaccines Trial Network (HVTN). As of December 31, 2011 it owned 16.1% interest in VGX Int��.
Inovio�� Solution
The Company�� synthetic vaccine platform consists of its SynCon vaccine design process and electroporation delivery technology. It has developed a preclinical and clinical stage pipeline of vaccines. The Company�� synthetic vaccines are designed to prevent a disease (prophylactic vaccines) or treat an existing disease (therapeutic vaccines). Its synthetic vaccine consists of a deoxyribonucleic acid (DNA) plasmid encoding a selected antigen! (s), which is introduced into cells of humans or animals with the purpose of evoking an immune response to the encoded antigen. The Company�� synthetic vaccines are designed to generate specific antibody and/or T-cell responses.
The Company�� SynCon technology provides processes that employ bioinformatics, which combine extensive genetic data and sophisticated algorithms. Its design process uses the genetic make-up of a common antigen(s) from multiple strains of a virus within a viral sub-type or taxonomic group (family) of pathogens, such as HIV, hepatitis C virus (HCV), human papillomavirus (HPV), influenza and other diseases to synthetically create a new antigen for the desired pathogen target that does not exist in nature. Its synthetic vaccine candidates are being delivered into cells of the body using its electroporation (EP) DNA delivery technology.
Cancer Synthetic Vaccines
The Company has two broad types of cancer vaccines: preventive (or prophylactic) vaccines, which are intended to prevent cancer from developing in healthy people, and treatment (or therapeutic) vaccines, which are intended to treat an existing cancer by strengthening the body�� natural defenses against the cancer. Two types of cancer preventive vaccines are available in the United States. The United States Food and Drug Administration (the FDA) has approved two vaccines, Gardasil and Cervarix that protect against infection by the two types of HPV-types 16 and 18-that cause approximately 70% of all cases of cervical cancer worldwide. In addition, Gardasil protects against infection by two additional HPV types, 6 and 11, which are responsible for about 90% of all cases of genital warts in males and females but do not cause cervical cancer.
Cervarix manufactured by GlaxoSmithKline, is composed of virus-like particles (VLPs) made with proteins from HPV types 16 and 18. Cervarix is approved for use in females��ages 10 to 25 for the prevention of cervical cancer caused by! HPV type! s 16 and 18. Gardasil manufactured by Merck, is approved for use in females for the prevention of cervical cancer, and some vulvar and vaginal cancers, caused by HPV types 16 and 18 and for use in males and females for the prevention of genital warts caused by HPV types 6 and 11. The vaccine is approved for these uses in females and males ages 9 to 26. The FDA has also approved a cancer preventive vaccine that protects against hepatitis B virus (HBV) infection.
Inovio�� VGX-3100 is designed to raise immune responses against the E6 and E7 genes of HPV types 16 and 18 that are present in both pre-cancerous and cancerous cells transformed by these HPV types. E6 and E7 are oncogenes that play an integral role in transforming HPV-infected cells into cancerous cells. In March 2011, it initiated a randomized, double-blind Phase II study of VGX-3100 delivered using the CELLECTRA intramuscular electroporation device in women with HPV Type 16 or 18 and diagnosed with, but not yet treated for, cervical intraepithelial neoplasia (CIN) 2/3. The study is designed to enroll 148 subjects. In January 2011, it announced the publication of a scientific paper in the journal Human Vaccines detailing potent immune responses in a preclinical study of its SynCon vaccine for prostate cancer targeting two antigens, prostate specific antigen (PSA) and prostate specific membrane antigen (PSMA).
In January 2011, the Company announced the regulatory approval of a Phase II clinical trial (WIN Trial) to treat leukemia utilizing its new ELGEN 1000 automated vaccine delivery device. The single dose level, Phase II study, called WT1 immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation. Cancer Vaccines encodes for hTERT, an antigen related to non-small cell lung, breast and prostate cancers. The vaccine is delivered using its electroporation delivery technology.
Infectious Disease Synthetic Vaccines
In Marc! h 2011, the Company announced the initiation of a follow-on open label, single dose Phase II clinical study in collaboration with ChronTech of the ChronVac-C HCV DNA vaccine delivered using its electroporation technology in treatment naive HCV infected individuals. Its HIV vaccines consist of candidates for HIV prevention, as well as therapy or treatment. PENNVAX-B is designed to target HIV clade B (most commonly found in the United States, North America, Australia and the European Union (EU). PENNVAX-G is designed to target HIV clades A, C and D, which are more commonly found in Asia, Africa, Russia and South America. This Phase I clinical study of PENNVAX-B (HVTN-080) vaccinated 48 healthy, HIV-negative volunteers to assess safety and levels of immune responses generated by Inovio�� PENNVAX-B vaccine delivered with its CELLECTRA electroporation device. PENNVAX-B is a SynCon vaccine that targets HIV gag, pol, and env proteins.The Company�� VGX-3400X targets H5N1. The vaccine consists of three distinct DNA plasmids coded for a consensus hemagglutinin (HA) antigen derived from different H5N1 virus strains; a consensus neuraminidase (NA) antigen derived from different N1 sequences; and a consensus nucleoprotein (NP) fused to a small portion of the m2 protein (m2E) based on a broader cross-section of influenza viruses in addition to H5N1 and H1N1. Conventional vaccines are strain-specific and have limited ability to protect against genetic shifts in the influenza strains they target. They are therefore modified annually in anticipation of the next flu season�� new strain(s). It is focused on developing DNA-based influenza vaccines able to provide broad protection against known as well as newly emerging, unknown seasonal and pandemic influenza strains.
Animal Health/Veterinary
VGX Animal Health, Inc. (VGX AH), a majority-owned subsidiary, has licensed LifeTide, a plasmid-based growth hormone releasing hormone (GHRH) technology for swine. LifeTide is one of onl! y four DN! A-based treatments approved for use in animals and is the only DNA-based agent delivered using electroporation that has been granted marketing approval (Australia). VGX AH is also developing a GHRH-based treatment for cancer and anemia in dogs and cats. It is developing a synthetic vaccine for foot-and-mouth disease (FMD) administered by its vaccine delivery technology. The FMD virus is one of the most infectious diseases affecting farm animals, including cattle, swine, sheep and goats, and is a serious threat to global food safety.
The Company competes with Crucell N.V, Sanofi-Aventis, Novartis, Inc., GlaxoSmithKline plc, Merck, Pfizer, AstraZeneca, Inc., Novartis, Inc., MedImmune and CSL.
Advisors' Opinion:- [By Sean Williams]
No fairytale ending
Fairytale endings work great in the movies, but you rarely see them come to fruition in the real world. Small-cap biopharmaceutical Inovio Pharmaceuticals (NYSEMKT: INO ) has seen shares nearly triple since April on the heels of multiple intriguing studies, but will the glass slipper fit over the long term?
No comments:
Post a Comment